| Not Yet Recruiting | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, an NCT07490301 | AbbVie | Phase 2 / Phase 3 |
| Not Yet Recruiting | Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Duct NCT07445295 | Chipscreen Biosciences, Ltd. | Phase 3 |
| Recruiting | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma NCT06904378 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcino NCT07475234 | Xiuchao Wang | Phase 1 / Phase 2 |
| Recruiting | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenoc NCT07214298 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT07089940 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Not Yet Recruiting | Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma NCT06981806 | Arsen Osipov | Phase 1 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combine NCT07165951 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 |
| Recruiting | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Cau NCT06989437 | Pfizer | Phase 2 / Phase 3 |
| Withdrawn | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma NCT06206876 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma NCT07096362 | University of Miami | Phase 2 |
| Recruiting | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation NCT06843551 | Benjamin Spieler | Phase 2 |
| Recruiting | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma NCT06648434 | Washington University School of Medicine | Phase 1 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Active Not Recruiting | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer NCT06646055 | Akeso | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic NCT06608927 | Arcus Biosciences, Inc. | Phase 3 |
| Recruiting | Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer NCT06600906 | University of California, San Francisco | — |
| Withdrawn | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-adva NCT06398587 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer NCT06168812 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel a NCT06390059 | NovoCure Ltd. | Phase 2 |
| Active Not Recruiting | BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT05558982 | Georgetown University | Phase 2 |
| Recruiting | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer NCT05685602 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer NCT05630183 | Agenus Inc. | Phase 2 |
| Withdrawn | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers NCT05737615 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259 | Belgian Group of Digestive Oncology | Phase 2 |
| Terminated | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma NCT04809766 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 | Flemming Forsberg | Phase 1 / Phase 2 |
| Completed | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line M NCT04935359 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan NCT05095064 | University Hospital, Antwerp | — |
| Completed | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies NCT05039177 | Erasca, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients NCT04888312 | Alligator Bioscience AB | Phase 1 / Phase 2 |
| Completed | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancre NCT04990037 | Cantargia AB | Phase 1 |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Completed | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancre NCT04493060 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologo NCT04666740 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer NCT04631445 | Translational Drug Development | N/A |
| Completed | Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma NCT04292743 | Georgetown University | Phase 1 |
| Completed | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cance NCT04581343 | Pancreatic Cancer Action Network | Phase 1 |
| Terminated | Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy i NCT04390763 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenoca NCT04329949 | Corcept Therapeutics | Phase 3 |
| Recruiting | Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Active Not Recruiting | A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pa NCT04523987 | National University Hospital, Singapore | Phase 1 |
| Terminated | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX NCT03450018 | British Columbia Cancer Agency | Phase 1 / Phase 2 |
| Terminated | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Ca NCT03610490 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequent NCT03331640 | AIO-Studien-gGmbH | Phase 2 |
| Active Not Recruiting | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer NCT02600949 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients NCT02732938 | Pfizer | Phase 2 |
| Completed | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma NCT02583477 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC NCT02501902 | Pfizer | Phase 1 |
| Completed | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Ca NCT02558894 | AstraZeneca | Phase 2 |
| Terminated | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic NCT02101021 | Sierra Oncology LLC - a GSK company | Phase 3 |
| Completed | CART-meso in Mesothelin Expressing Cancers NCT02159716 | University of Pennsylvania | Phase 1 |